期刊文献+

冠心病患者血清可溶性白细胞介素6受体变化及意义 被引量:3

Clinical Significance of Serum sIL-6R in Patients with Acute Myocardial Infarction
下载PDF
导出
摘要 目的 探讨急性心肌梗死 (AMI)患者可溶性的白介素 6受体水平变化与心功能的关系。方法 用酶联免疫吸附法检测AMI患者 (AMI组 ) 2 2例 ,稳定性心绞痛患者 (SA组 ) 33例的血清可溶性白介素 6受体(sIL 6R)水平变化 ,并与 30例健康对照者 (对照组 )比较。结果 ①AMI组血清sIL 6R水平明显高于SA组 (P <0 .0 5 )及对照组 (P <0 .0 1) ,且随心功能恶化而逐渐升高 ,KillipⅡ~Ⅳ级各亚组间差异有非常显著意义 (P <0 .0 1)。②sIL 6R水平与左室射血分数呈显著负相关 (r=- 0 .78,P <0 .0 1)。结论 sIL 6R水平可作为AMI诊断的实验指标 ,结果提示sIL 6R参与了心梗的发生。 Objective To explore the relation between the serum level of soluble interleukin 6 receptor(sIL 6R) and cardiac function in patients with acute myocardial infarction(AMI).Methods Serum levels of sIL 6R in 22 patients with AMI (AMI group ) and 18 patients with stable angina(SA group) were examined with enzyme linked immunosorbent assay(ELISA) and data were compared with control group of 30 age matched healthy subjects.Results ①Serum levels of sIL 6R were significantly higher in patients with AMI than those with SA(P<0.05) and controls (P<0.01).More specifically,they were progressively elevated with severity of cardiac function and there were significant differences in subgroups of Killip Ⅱ~Ⅳ(P<0.01).②The sIL 6R levels were inversely related to LVEF(r=-0.78,P<0.01).Conclusion The serum level of sIL 6R can serve as experimental parameter for diagnosis of AMI,which suggests that sIL 6R may be involved in pathogenesis of AMI.
出处 《潍坊医学院学报》 2003年第2期136-137,共2页 Acta Academiae Medicinae Weifang
关键词 冠心病 心肌梗死 急性 可溶性白细胞介素6受体 血清 AMI Cornary heart disease Myocardial infarction,acute Soluble interleukin 6 receptor
  • 相关文献

参考文献3

二级参考文献33

  • 1彭善云,康新具,凌世淦,宋晓国,王嘉玺,马贤凯.白介素6生物活性简易测定法及其临床应用[J].军事医学科学院院刊,1994,18(1):72-74. 被引量:25
  • 2[1]Cullen P,von Eckardstein A,Assmann G. Diagnosis and maragenent of new cardiovascular risk factors[J]. Eur Heart J, 1998,19:13 - 19.
  • 3[2]Ross R. Atherosclerosis - an inflammatory disease[J]. N Eng J Mec, 1999,340:115-126.
  • 4[3]Biasucci LM,Golizzi C,et al. Role of inflammation in the pathogenesis on un stable coronary artery diseases[J]. Scand J Clin Lab Invest, 1999.50. (supp 230) : 12-22.
  • 5[4]Depre C,Wijns W,Annie M,et al. Pathology of unstable plaque:correlauon with the clinic al severity of acute coronary syndromes[J]. J Am Coll Cardi ol,l997,30:694-702
  • 6[5]Newby AC,Zaltsman AB. Fibrous cap formation or destruction -the critical importance of vascular smooth muscle cell proliferation, migration and ma trix formation[J]. Cardiovasc Res, 1999, 41 : 345-360.
  • 7[6]van der Wal AC,Pidk JJ,de Boer OJ,et al. Recent onset activation of the plaque immune response iR coronary lesions underlying acute coronary syndromes[J]. Heart, 1998,80 : 14-18.
  • 8[7]Onno J,Allard C,et al. Leucocyte recruitment in rupture prone regions of lipid-rich plaques:a prominent role for neovascularization[J]? Cardiovasc Res, 1 999, 41 : 443-449.
  • 9[8]Collins T,Read MA,Neish AS,et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers[J]. FASEB J,1995,9:899-909.
  • 10[9]Peng HB,Libby L,Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B[J]. J Biol Chem, 1995,270:14214-14219,

共引文献32

同被引文献18

  • 1EIKEN H G, OIE E, DAMAS J K, et al. Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end stage human heart failure[J]. Eur J Clin Invest, 2001,31:389-397.
  • 2AUER J, BCRENT R, LASSNIG E, et al. C reactive protein and coronary arterydisease[J]. Jpn Heart J, 2002,43 (6) : 607-619.
  • 3FISCHER P, HILFIKER-KIEINER D. Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects[J]. British Journal of Pharmacology, 2008,153(6) :414-427.
  • 4RIDLER P M, HENEKERRS C H, BUHNG J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J].N Enlg L J Med, 2000,342(12):836-843.
  • 5EIKEN H G,OIE E,DAMAS J K,et al.Myocardial gene expression of leukaemia inhibitory factor,interleukin-6 and glycoprotein 130 in end-stage human heart failure[J].Eur J Clin Invest,2001,31:389-397.
  • 6FISCHER P,HILFIKER-KLEINER D.Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects[J].Bri J Pharm,2008,153(6):414-427.
  • 7WINGING S,KENER F,STEINBACH G,et al.Specificity of cardiac troponin T in renal disease[J].Clin Chem Lab Med,1998,36(2):87-92.
  • 8KAVSAK P A,MACRAE A R,LUSTIG V,et al.The impact of the ESC/ACCredefintion of myocardial infarctin and new sensitive troponin assay on the frequency of acute myocardial infarction[J].Am Heart J,2006,152:118-125.
  • 9Okopien B, BasiakM, M adejA, et al. Markers of inflammatory process in stable and unstable coronary arterydisease[J]. Pol Merkur Lekarsk,2006,21( 121 ) : 69-72.
  • 10Dubinski A, Zdrojewcz Z. The role of interleukin 6 indevelopment and progression of atherosclerosis[J]. Pol Merkur Lekarsk, 2007,22 (130) : 291-294.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部